Uremic cardiomyopathy (UC) is the cardiac remodelling that occurs in patients with chronic kidney disease (CKD). It is characterised by a left ventricular (LV) hypertrophy phenotype, diastolic dysfunction and generally preserved LV ejection fraction. UC has a major role mediating the increased rate of cardiovascular events, especially heart failure related, observed in patients with CKD. Recently, the use of T1 and T2 mapping techniques on cardiac MRI has expanded the ability to characterise cardiac involvement in CKD. Native T1 mapping effectively tracks the progression of interstitial fibrosis in UC, whereas T2 mapping analysis suggests the contribution of myocardial oedema, at least in a subgroup of patients. Both T1 and T2 increased values were related to worsening clinical status, myocardial injury and B-type natriuretic peptide release. Studies investigating the prognostic relevance and histology validation of mapping techniques in CKD are awaited.

T1 and T2 Mapping in uremic cardiomyopathy: an update / Arcari, Luca; Camastra, Giovanni; Ciolina, Federica; Danti, Massimiliano; Cacciotti, Luca. - In: CARDIAC FAILURE REVIEW. - ISSN 2057-7540. - 8:(2022). [10.15420/cfr.2021.19]

T1 and T2 Mapping in uremic cardiomyopathy: an update

Arcari, Luca
Primo
;
Ciolina, Federica;
2022

Abstract

Uremic cardiomyopathy (UC) is the cardiac remodelling that occurs in patients with chronic kidney disease (CKD). It is characterised by a left ventricular (LV) hypertrophy phenotype, diastolic dysfunction and generally preserved LV ejection fraction. UC has a major role mediating the increased rate of cardiovascular events, especially heart failure related, observed in patients with CKD. Recently, the use of T1 and T2 mapping techniques on cardiac MRI has expanded the ability to characterise cardiac involvement in CKD. Native T1 mapping effectively tracks the progression of interstitial fibrosis in UC, whereas T2 mapping analysis suggests the contribution of myocardial oedema, at least in a subgroup of patients. Both T1 and T2 increased values were related to worsening clinical status, myocardial injury and B-type natriuretic peptide release. Studies investigating the prognostic relevance and histology validation of mapping techniques in CKD are awaited.
2022
T2 mapping; uremic cardiomyopathy; cardiac MRI; chronic kidney disease; fibrosis; native T1 mapping; oedema
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
T1 and T2 Mapping in uremic cardiomyopathy: an update / Arcari, Luca; Camastra, Giovanni; Ciolina, Federica; Danti, Massimiliano; Cacciotti, Luca. - In: CARDIAC FAILURE REVIEW. - ISSN 2057-7540. - 8:(2022). [10.15420/cfr.2021.19]
File allegati a questo prodotto
File Dimensione Formato  
Arcari_T1 and T2 _2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 705.97 kB
Formato Adobe PDF
705.97 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1656775
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 8
  • ???jsp.display-item.citation.isi??? ND
social impact